What is Cureous Labs?
Cureous Labs operates at the intersection of medical technology and patient safety, specializing in the development of intelligent automatic patient repositioning systems. The company addresses critical challenges in healthcare, specifically the prevention of bedsores and bedfalls, which remain significant concerns for patients with limited mobility. By automating the repositioning process, Cureous Labs effectively reduces the physical burden on caregivers while simultaneously enhancing patient comfort and clinical outcomes.
The company's market position is bolstered by its dual-focus approach, catering to both high-acuity hospital settings and the burgeoning home-care market. With a proven track record among leading healthcare providers in India, Cureous Labs has established itself as a vital player in the health-tech ecosystem, prioritizing innovation that directly improves the quality of life for vulnerable populations.
How much funding has Cureous Labs raised?
Cureous Labs has raised a total of $190K across 1 funding round:
Seed
$190K
Seed (2025): $190K with participation from Inflection Point Ventures and Anthill Ventures
Key Investors in Cureous Labs
Inflection Point Ventures
Inflection Point Ventures is a prominent Indian angel investing platform that provides both financial backing and non-monetary support to startups, leveraging a vast network of CXOs and professionals to foster scalability.
Anthill Ventures
Anthill Ventures is a speed-scaling venture capital firm that focuses on accelerating startups within the Urban, Climate, Media, and Health Tech sectors by providing global access and strategic guidance.
What's next for Cureous Labs?
With this late-stage funding secured, Cureous Labs is poised to enter a phase of rapid commercial expansion and product refinement. The strategic roadmap likely includes scaling its distribution networks to penetrate international markets and investing in R&D to further integrate AI-driven monitoring into its existing hardware. As the company transitions from a growth-stage entity to a more mature market leader, the focus will shift toward optimizing supply chain efficiencies and solidifying its reputation as a standard-bearer for patient-centric medical technology. The continued support from its investor base provides not only the necessary financial runway but also the strategic guidance required to navigate the complexities of the global healthcare landscape.
See full Cureous Labs company page
